Day: April 28, 2021

Results from Calithera Biosciences’ CANTATA Study to Be Presented at 2021 ASCO Annual Meeting

Written by Customer Service on April 28, 2021. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that final results from the CANTATA clinical study will be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting taking place virtually June 4-8, 2021. Earlier this year, Calithera announced topline results from the Phase 2 CANTATA trial, which evaluated the efficacy and safety of the company’s glutaminase inhibitor, telaglenastat, in combination with cabozantinib versus placebo with cabozantinib in patients with advanced or metastatic renal cell carcinoma (RCC) who had been treated with one or...

Foghorn Therapeutics Appoints Ian Smith to its Board of Directors

Written by Customer Service on April 28, 2021. Posted in Public Companies.

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) — Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of Ian Smith to its Board of Directors effective, April 27. “Ian is a proven biotechnology leader with a diverse skill set, and I am excited to welcome him to our Board at this important time in the company’s evolution,” stated Adrian Gottschalk, Foghorn’s Chief Executive Officer. “Ian has been advising the company since early 2020 on various initiatives including business development and equity financing strategies as well as company progression and development. The addition of Ian to our Board brings significant business experience and capital...

AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update

Written by Customer Service on April 28, 2021. Posted in Public Companies.

Reported potent interim immunogenicity results for anti-pTau Alzheimer’s vaccine in ongoing Phase 1b/2a study, which support further development into Phase 2/3 Initiated first-in-human clinical study for next-generation alpha-synuclein PET diagnostic with results expected in Q3 2021 Advanced multiple candidates targeting the NLRP3 inflammasome pathway for CNS and non-CNS indications Strong financial position of CHF 216.1 million in cash ensures the Company is fully financed through at least Q1 2024LAUSANNE, Switzerland, April 28, 2021 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the quarter ended March 31, 2021. The Company also provided an overview of its recent clinical and corporate...

Trillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance Changes

Written by Customer Service on April 28, 2021. Posted in Public Companies.

TTI-622 monotherapy shows 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses, including 3 new responses (1 Complete Response (CR) + 2 Partial Responses (PRs)) since last data disclosure; TTI-621 monotherapy shows 18-29% ORR in R/R T- and B-cell lymphomas at 0.2-2.0 mg/kg doses, including 3 new responses (1 CR + 2 PRs) in cutaneous T-cell lymphoma (CTCL) since last data disclosure; TTI-622 and TTI-621 have been well tolerated at doses up to 18 mg/kg and 2.0 mg/kg weekly, respectively; neither drug candidate reached a maximum tolerated dose (MTD) level; Phase 1b/2 program across seven hematologic and solid tumor indications has been initiated, with studies across nine patient settings to start over approximately the next twelve months; Scott Myers joins the Board of Directors; Robert Kirkman and...

Sio Gene Therapies Announces Four Upcoming Oral Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy

Written by Customer Service on April 28, 2021. Posted in Public Companies.

NEW YORK, and RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) — Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced four upcoming oral presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), to be held virtually between May 11th to May 14th, 2021. The AXO-AAV-GM1 presentation will include a review of patient-level data on safety and efficacy at 6 months follow up from the low-dose cohort of the Company’s ongoing clinical study. Additionally, Dr. Cynthia Tifft, the lead investigator for the study, will present 6-month biomarker data from cerebrospinal fluid (CSF) in the 5 children who received intravenous AAV9 gene therapy. Oral...

Amicus Therapeutics Recognized as a Great Place to Work® in Europe

Written by Customer Service on April 28, 2021. Posted in Public Companies.

Great Place to Work® Certification in the United Kingdom, Spain, Italy and Germany PHILADELPHIA, April 28, 2021 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has been recognized by the prestigious Great Place to Work® Institute as among the best places to work in the United Kingdom, Spain, Italy and Germany. The company has also been recognized with a Best Workplaces Bavaria designation. Great Place to Work® is an international research and consulting institute that supports organizations in developing their corporate and workplace culture. This certification indicates that an organization’s workplace culture is validated through anonymous employee feedback, based...

BioVie to Present at 2021 B. Riley Securities’ Neuroscience Conference

Written by Customer Service on April 28, 2021. Posted in Public Companies.

SANTA MONICA, Calif., April 28, 2021 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and, pending closing of the announced transaction with NeurMedix, neurological and neuro-degenerative disorders and certain cancers, today announced the participation of its President and Chief Executive Officer Cuong Do at the 2021 B. Riley Securities’ Neuroscience Conference. Mr. Do is scheduled to present on Wednesday, April 28 at 3:00 PM Eastern Time and will discuss BioVie’s pending acquisition of NeurMedix’s assets and plans going forward for Alzheimer’s and Parkinson’s. BioVie Presentation Details Date: Wednesday, April 28, 2021 Time: 3:00 PM Eastern Time A live webcast of BioVie’s presentation...

Brookfield Infrastructure Encourages Inter Pipeline to Increase Transparency and Put Shareholders First

Written by Customer Service on April 28, 2021. Posted in Mergers And Acquisitions.

More than 75 days have passed since Brookfield Infrastructure announced its intention to make the Offer, and yet the IPL Special Committee has not provided shareholders with any real update regarding the Strategic Review process IPL’s recent update on the Heartland Petrochemical Complex raises many more questions than it answers; the Company has been challenged to identify a partner for this project since commencement of a process in late 2019 Based on the current trading price of Brookfield Infrastructure Corporation (NYSE: BIPC; TSX: BIPC) class A exchangeable shares as of market close on April 27, 2021, the Offer now implies aggregate consideration to IPL shareholders of approximately C$17 per share (based on prorating), representing a premium of 30% to IPL’s 30-day volume-weighted average share price prior to the date that Brookfield...

Stabilis Solutions Announces First Quarter Earnings Call

Written by Customer Service on April 28, 2021. Posted in Public Companies.

Houston, TX, April 28, 2021 (GLOBE NEWSWIRE) — Stabilis Solutions, Inc. (OTCQX:SLNG) (“Stabilis”), a leading provider of energy transition services including hydrogen and liquefied natural gas (“LNG”) fueling solutions, is pleased to announce that it will release its first quarter 2021 financial results on Wednesday, May 5, 2021 after the market closes. The Company has scheduled a conference call on Thursday, May 6, 2021 at 10:00 a.m. eastern time (9:00 a.m. central). Dial-in InformationUnited States & Canada: +1 877-545-0320; passcode 225377 International: +1 973-528-0016; passcode 225377 Webcast: Stabilis Solutions 1Q21 Earnings Call Replay InformationUnited States & Canada: +1 877-481-4010; passcode 40949 International:+1 919-882-2331; passcode 40949 A replay of the call will be available...

Versus Systems to Host an Interactive Investor Event on May 20th

Written by Customer Service on April 28, 2021. Posted in Public Companies.

Executive team to update investors via a gamified presentation on recent developments, growth strategy and the partnership with Xcite Interactive LOS ANGELES, April 28, 2021 (GLOBE NEWSWIRE) — Versus Systems Inc. (“Versus” or the “Company”) (Nasdaq: VS) (FRANKFURT: BMVB) announced today that it will host its first ever virtual investor day on Thursday, May 20th. The interactive, gamified presentation will be held on the Versus Systems website and will begin at 1:30 p.m. Pacific/ 4:30 p.m. Eastern. Versus Systems’ executive management team will make a series of presentations to investors covering recent developments, its strategies and tactics for growth in markets around the world, and details and plans for its recently announced partnership with Xcite Interactive. The presentation will be accessible via the Versus Systems website...

Day: April 28, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals